US 12,187,796 B2
ILT3-binding agents and methods of use thereof
Suzanne Christine Crawley, Brisbane, CA (US); Jer-Yuan Hsu, San Bruno, CA (US); Daniel David Kaplan, San Mateo, CA (US); Betty Chan Li, Millbrae, CA (US); Vicky Yi-Bing Lin, Cupertino, CA (US); Seth Malmersjö, Menlo Park, CA (US); Kevin James Paavola, San Francisco, CA (US); Julie Michelle Roda, Pacifica, CA (US); and Yan Wang, Foster City, CA (US)
Assigned to NGM Biopharmaceuticals, Inc., South San Francisco, CA (US)
Filed by NGM Biopharmaceuticals, Inc., South San Francisco, CA (US)
Filed on Aug. 2, 2023, as Appl. No. 18/364,285.
Application 18/364,285 is a division of application No. 17/125,734, filed on Dec. 17, 2020, granted, now 11,760,802.
Claims priority of provisional application 62/950,434, filed on Dec. 19, 2019.
Prior Publication US 2024/0043533 A1, Feb. 8, 2024
Int. Cl. A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/565 (2013.01)] 26 Claims
 
1. A binding agent that specifically binds human immunoglobulin-like transcript 3 (ILT3), comprising:
(a) a heavy chain variable region (VH) comprising a VH-complementarity determining region (CDR) 1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 117 and a light chain variable region (VL) comprising a VL-complementarity determining region (CDR) 1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 118;
(b) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 119 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:120;
(c) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 109 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:110;
(d) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO:113 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:114;
(e) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO:115 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 116; or
(f) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 121 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:122.